Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1992-12-04
1995-01-10
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514934, A61K 3121
Patent
active
053807545
ABSTRACT:
Multiple daily applications of a topical composition having as the active ingredients an anesthetic and a surfactant with anti-vital activity decrease the time of healing of herpes simplex viral lesions from approximately seven to ten days to five to six days, as well as decrease inflammation and pain. The composition is applied to the lesions daily, approximately every four hours, preferably beginning at the prodromal stage of infection. Relief is almost immediate, and is characterized by decreased pain, swelling, and more rapid healing as compared with the untreated lesion.
REFERENCES:
patent: 4139630 (1979-02-01), Asculai et al.
patent: 4462986 (1984-07-01), Smith
patent: 4507281 (1985-03-01), Asculai et al.
patent: 4628063 (1986-12-01), Haines et al.
patent: 4874794 (1989-10-01), Katz
patent: 5070107 (1991-12-01), Katz
patent: 5071879 (1991-12-01), Katz
European Patent Application No. 86100939.7, Showa Denko K. K., published Aug. 6, 1986.
I. Tentsova, et al., "Stability of solutions of dicain in the presence of surfactants," All-Union Scientific Research Institute of Pharmacy, Moscow (Jun. 3, 1988) (English translation included).
Adriani and Zepernick, "Clinical Effectiveness of Drugs Used for Topical Anesthesia" JAMA 188(8):711-716 (May 1964).
Barry, B. W., "Mode of Action of Penetration Enhancers In Human Skin" J. Controlled Release 6:85-97 (1987).
Cassuto, Jean, "Topical Local Anaesthetics and Herpes Simplex" The Lancet 8629:100-101 (Jan. 14, 1989).
Friedman-Klein, et al., "Treatment of recurrent genital herpes with topical alpha interferon gel combined with nonoxynol 9" J. Am. Acad. Dermatol. 15(5):989-994 (Nov. 1986).
Fuchs and Levanon, "Inhibition of Adsorption of West-Nile and Herpes Simplex Viruses by Procaine" Archives of Virology 56:163-168 (1978).
Gangarosa, Louis P., "Newer Local Anesthetics and Techniques for Administration" J. Dent. Res. 60(8): 1471-1480 (Aug. 1981).
Goldberg, Charles B., "Topical Surfactant Therapy for Recurrent Herpes Simplex" The Lancet 8509:755 (Sep. 27, 1986).
Kawakatsu and Sakata, "Topical solutions containing amphoteric surfactants for prevention of viral infections" Pharmacology vol. 111, Chemical Abstracts, No. 145792s (1989).
Nicolson, Garth L., "Cell Shape Changes and Transmembrane Receptor Uncoupling Induced by Tertiary Amine Local Anesthetics" J. Supramolecular Structure 5:65-72 (1976).
Nicolson et al., "Effects of Local Anesthetics On Cell Morphology and Membrane-Associated Cytoskeletal Organization In Balb/3T3 Cells" J. Cell Biology 68:395-402 (1975).
Nixon et al., "Interspecies Comparisons of Skin Irritancy" Toxicology and Applied Pharmacology 31:481-490 (1975).
Poste et al., "Local anesthetics affect transmembrane cytoskeletal control of mobility and distribution of cell surface receptors" Proc. Nat. Acad. Sci. U.S.A. 72(11):4430-4434 (Nov. 1975).
Reichman, et al., "Treatment of Recurrent Genital Herpes Simplex Infections With Oral Acyclovir A Controlled Trial" JAMA 251(16) 2103-2107 (Apr. 27, 1984).
Shimakage, et al., "Local injection of human fibroblast interferon-.beta. effective in malignant skin tumors" Skin Res. 24(5):732-741 (1982) (Biol. Abst. 76 (11):8998, No. 81880).
Svobodova, et al., "Long-term cultivation of cells derived from guinea pig tongue" Acta Virol. (Prague) 21(4):349 (1977) (Biol. Abst. 66(1):596, No. 6159 (1978)).
Vontver, et al., "Clinical course and diagnosis of genital herpes simplex virus infection and evaluation of topical surfactant therapy" Am. J. Obstet. Gynecol. 133(5):548-554 (1979).
Sarpotdar et al., "Evaluation of penetration enhancement of lidocaine by nonionic surfactants through hairless mouse skin in vitro" Journal of Pharmaceutical Sciences 75(2):176-181 (Feb. 2, 1986).
"Evaluation of Topical Antiviral Therapy In A Primary Genital Herpes Simplex Virus Type 2 (HSV-2) Infection of Guinea Pigs" Final Report by Earl R. Kern, Ph.D., Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Ala., May 16, 1990.
Poste and Reeve, "Inhibition of virus-induced cell fusion by local anesthetics and phenothiazine tranquilizers," J. Gen. Virol. 16:21-28 (1972).
Wunderlich and Sydow, "Lytic action of neurotropic drugs on retroviruses in vitro," Eur. J. Cancer, 16:1127-32 (1980).
Miller and Lenard, "Antihistaminics, local anesthetics, and other amines as antiviral agents," Proc. Natl. Acad. Sci. U.S.A. 6:3605-3609 (1981).
Merchant et al., "Unsaturated and free fatty acid inhibition of herpes simplex virus," Microbios Letters 35:71-78 (1987).
L. R. Stanberry, E. R. Kern, J. R. Richards, T. M. Abbott, and J. C. Overall Jr., "Genital Herpes in Guinea Pigs: Pathogenesis of the Primary Infection and Description of Recurrent Disease" J. Infect. Dis., 146:397-404 (1982).
W. R. Hubler, Jr., T. D. Felber, D. Troll, and M. Jarratt, "Guinea Pig Model for Cutaneous Herpes Simplex Virus Infection" J. Invest. Dermatol., 62:92-95 (1974).
M. Lieberman, T. W. Schaefer, and P. E. Came, "Chemotherapy of Cutaneous Herpes Virus Infection of Hairless Mice" J. Invest. Derm., 60:203-206 (1973).
J. Descamps, E. DeClercq, P. J. Barr, A. S. Jones, R. T. Walker, P. F. Torrence, and D. Shugar, "Relative Potencies of Different Anti-Herpes Agents in the Topical Treatment of Cutaneous Herpes Simples Virus Infection of Athymic Nude Mice" Antimicrob. Agents Chemother., 16:680-682 (1979).
T. J. Hill, H. J. Field, W. A. Blyth, "Acute and Recurrent Infection with Herpes Simplex Virus in the Mouse: a Model for Studying Latency and Recurrent Disease" J. Gen. Virol., 28:341-353 (1975).
Poste et al. 70 CA: 147965s 1972.
Wunderlech et al. 93 CA:230706j 1980.
Miller et al. 95 CA: 90885p 1981.
Vickonova et al. 79 CA:38916x 1973.
Asculai et al. 85 CA:83237m 1976.
Asculai et al. 86 CA:195230f 1977.
Merchant et al. 108 CA 15820q 1988.
Merck Index 10th Ed #'s 1020, 3840, 5977, 7659, 8421, 8474, 8654, 9014.
Kronenthal Richard L.
Miller Bruce W.
Cintins Marianne M.
Travers Russell
Virotex Corporation
LandOfFree
Topical composition enhancing healing of viral lesions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Topical composition enhancing healing of viral lesions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical composition enhancing healing of viral lesions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-850944